A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations

Recruiting

Phase 1

ALTA3263A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations

Sponsor:

Alterome Therapeutics, Inc.

Code:

NCT06835569

Conditions

Cancer

PDAC - Pancreatic Ductal Adenocarcinoma

NSCLC (Non-small Cell Lung Cancer)

CRC (Colorectal Cancer)

Advanced Solid Tumors

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

ALTA3263

cetuximab

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-02-28. This information was provided to ClinicalTrials.gov by Alterome Therapeutics, Inc. on 2025-12-10.